ANGIODYNAMICS INC

AngioDynamics, Inc.

Overview

• Medical technology company focused on expanding treatment options and improving patient outcomes for cardiovascular disease and cancer.
• Designs, manufactures and sells products and technologies used by clinicians in interventional radiology, vascular access, peripheral vascular disease, endovascular therapies and related areas.
• Strategy centers on innovative R&D, expanding clinical and regulatory pathways, and customer-focused sales performance.

Business segments and product categories

Med Tech

• Auryon: Atherectomy system using an optimized wavelength and short pulse to remove plaque with integrated aspiration; supports femoral, pedal and radial access for peripheral arterial disease treatment.
• Thrombus Management: AlphaVac Mechanical Thrombectomy System; AngioVac venous drainage cannula and circuit; Uni-Fuse and Uni-Fuse+ thrombolytic catheter systems.
• NanoKnife: NanoKnife IRE Ablation System (uses low-energy direct current pulses to permanently open pores in cell membranes); 510(k) cleared by the FDA; expanded 510(k) clearance for prostate tissue ablation (Dec 2024); MDR/CE considerations (Feb 2026).
• Peripheral Products (Interventional Devices): Line of angiographic catheters, guidewires, drainage catheters and micropuncture kits (examples: Soft-Vu, Mariner hydrophilic catheters, Accu-Vu sizing catheters, NiT-Vu micro guidewires).
• VenaCure EVLT: Endovenous laser therapy system to treat superficial venous disease (varicose veins); 1470 nm laser with NeverTouch tip.
• Solero Microwave Tissue Ablation: Microwave generator and applicators for soft tissue ablation; single-applicator system capable of creating ablations in minutes.
• IsoLoc Endorectal Balloon and Alatus Vaginal Balloon Packing System: Tools to optimize radiation therapy and reduce treatment-related discomfort.

Med Device

• Ports and vascular access systems: SmartPort, SmartPort+, BioFlo with Endexo Technology, Xcela Plus for central venous access and repeated infusions.
• BioFlo materials with Endexo designed to resist thrombus formation; Vortex port design to improve flow and cleaning; PASV valve technology to resist backflow and reduce catheter-related complications.
• Venous access and interventional devices: catheters, guidewires, drainage products and micropuncture kits for diagnostic and therapeutic procedures.

Manufacturing, operations and locations

• Headquarters: Latham, New York.
• Manufacturing sites: Queensbury, NY (135,000 sq ft); Glens Falls, NY (21,000 sq ft).
• Distribution and other operations: Marlborough, MA (17,200 sq ft distribution); Rehovot, Israel (4,300 sq ft); additional sales offices in other jurisdictions.
• Plans to move certain manufacturing to third-party manufacturers globally, including locations in the U.S., Costa Rica, Latvia, Italy, Israel and China; restructuring activities expected to complete in Q1 fiscal year 2027.
• Facilities certified to ISO 13485 and MDSAP; products manufactured under FDA Quality System Regulation (QSR) requirements.

Customers and channels

• Primary customers: hospitals and physicians.
• Sales model: direct sales in the U.S.; international sales through a mix of direct sales and distributors.
• Key clinician customers: interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional/surgical oncologists and critical care nurses.
• International distribution: approximately 75% of international revenues are sourced through distributors; international sales represented about 14% of net sales for the fiscal year ended May 31, 2026.

People

• Approximately 632 full-time employees as of May 31, 2026.
• No employees represented by a labor union.
• Ongoing focus on talent development and retention.

Regulatory, quality and compliance

• Products regulated by the FDA with clearance or approval via 510(k) or PMA pathways as applicable; subject to post-market requirements including QSR, labeling and adverse event reporting.
• MDR CE marking considerations for the EU market; ongoing MDR compliance and data requirements.
• Reliance on international regulatory frameworks and quality systems for manufacturing and post-market surveillance; some regulatory approvals outside the U.S. supported through distributors.
• MDSAP certification permits a single audit to satisfy multiple regulatory authorities’ requirements.

Corporate actions and divestitures

• June 2023: Sale of the BioSentry product line to Merit Medical Systems, Inc.
• February 15, 2024: Sale of PICC and Midline businesses (including C3 Wave tip location asset) to Spectrum Vascular.
• February 29, 2024: Discontinued RadioFrequency Ablation and Syntrax product lines.
• Strategic focus on transforming into a higher-growth, higher-margin medical technology company through divestitures and portfolio optimization.